San Diego’s
healthtech industry,
in focus.

QuidelOrtho said this week that it has completed the acquisition of UK-based Lex Diagnostics for about $100 million in cash.

the gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses.

Turquoise has now raised a total of $95.3M in total equity funding and is backed by Adams Street Partners, Andreessen Horowitz, Oak HC/FT, and Yosemite.

To take over Surf, Halozyme is paying $300 million upfront, subject to customary purchase price adjustments, and up to $100 million in development and regulatory milestones.

LivsMed Inc., a Seoul-based minimally invasive surgical device company, has raised approximately $94 million (₩135.9 billion) in South Korea’s largest KOSDAQ IPO of 2025.

In June, Carlsmed (Nasdaq:CARL) announced its plans to go public, eventually closing the IPO about a month later.

Beken Bio has now raised $750,000, including investments from Boot64, the New Orleans BioFund and 1834 Ventures, a $20 million fund backing startups connected to the Tulane community.

Bioavailable supplement brand Cymbiotika led the charge, closing a $25 million funding round to expand its premium nutrition offerings.

The investment will provide XiFin with financial flexibility to expand its next-generation RCM solutions, pursue growth opportunities, and continue advancing AI-driven healthcare innovations.

The offering, structured as a best-efforts placement through Maxim Group, includes provisions for inducement warrants already outstanding, which could add more shares to the market if exercised.